birb 796 has been researched along with angiotensinogen in 1 studies
Studies (birb 796) | Trials (birb 796) | Recent Studies (post-2010) (birb 796) | Studies (angiotensinogen) | Trials (angiotensinogen) | Recent Studies (post-2010) (angiotensinogen) |
---|---|---|---|---|---|
137 | 5 | 80 | 3,606 | 78 | 875 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Al-Saadi, N; Dechend, R; Feldt, S; Fiebeler, A; Fischer, R; Gapeljuk, A; Gratze, P; Haller, H; Luft, FC; Madwed, JB; Meiners, S; Muller, DN; Park, JK; Schirdewan, A; Shagdarsuren, E; Wellner, M | 1 |
1 other study(ies) available for birb 796 and angiotensinogen
Article | Year |
---|---|
p38 mitogen-activated protein kinase inhibition ameliorates angiotensin II-induced target organ damage.
Topics: Angiotensin II; Angiotensinogen; Animals; Animals, Genetically Modified; Cardiovascular Diseases; Disease Models, Animal; Kidney Diseases; Male; Naphthalenes; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Pyrazoles; Rats; Rats, Sprague-Dawley; Renin | 2007 |